



Pharmacotherapy for Alzheimer's Disease

Guest Editor:

Dr. Gabriela Dumitrița Stanciu

Advanced Research and
Development Center for
Experimental Medicine “Prof.
Ostin C. Mungiu”, “Grigore T.
Popa” University of Medicine and
Pharmacy of Iasi, Iasi, Romania

Deadline for manuscript
submissions:

30 October 2024

Message from the Guest Editor

Despite extensive knowledge on the molecular basis of AD, advancements in developing therapies that truly modify the progression of the disease have proven to be elusive. The ability of the editing system tools, repurposing current therapeutics or utilizing multi-target-directed ligands, presents a promising opportunity to elucidate the fundamental mechanisms driving AD pathogenesis and to discover new therapeutic pathways. This strategy has the potential to facilitate the identification of target molecules and the development of innovative preclinical disease models, thus providing hopeful prospects for therapeutic intervention. Authors are invited to submit original research and review articles highlighting recent findings in the pharmacotherapy of Alzheimer's disease. These includes, but are not limited to, novel molecular mechanisms and potential therapeutic targets, developing or repurposing drugs with the ability to target multiple disease features or exploring the risks and benefits of cannabinoid-based drugs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com